2A Biosciences develops small molecule drugs targeting inflammation through the use of 2A agonists. The company focuses on addressing the unmet medical needs associated with inflammatory diseases by enhancing the therapeutic efficacy of these compounds.
Funding
$3.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many inflammatory diseases lack effective treatments, leading to significant unmet medical needs. Current therapies often have limited efficacy or undesirable side effects.
Solution
2A Biosciences is developing a new class of small molecule drugs, 2A agonists, designed to target and modulate inflammation. By selectively activating the 2A receptor, these compounds aim to provide a more targeted approach to treating inflammatory conditions. The company focuses on enhancing the therapeutic efficacy of these agonists to address the limitations of existing treatments and improve patient outcomes.
Target Audience
The primary target audience includes individuals suffering from inflammatory diseases and healthcare providers seeking more effective treatment options.
Features
- Development of novel small molecule 2A agonists.
- Targeted approach to modulating inflammation.
- Focus on enhancing therapeutic efficacy.